Abstract
GM-CSF has been used successfully in autologous BMTs, and more recently in patients undergoing allogeneic BMT, for acute or chronic leukemia. We report two patients with hepatitis-related aplastic anemia who received recombinant human GM-CSF following HLA-identical sibling allogeneic BMTs. Both patients were conditioned with CY 200 mg/kg given over 4 days and received GM-CSF at 250 μg/m2 beginning 6 h after marrow infusion and continuing daily until the absolute neutrophil count was > 1.0 X 109/l for 2 days. Both patients had prompt engraftment, achieving an absolute neutrophil count of > 0.5 X 109/l on day 13. Neither patient had side-effects attributable to the GM-CSF although one patient developed severe acute GVHD after the cessation of GM-CSF therapy. Our experience suggests that GM-CSF can be safely used in aplastic anemia patients undergoing BMT and that GM-CSF may be useful to decrease the incidence of graft failure associated with less intensive conditioning regimens.
| Original language | English |
|---|---|
| Pages (from-to) | 173-175 |
| Number of pages | 3 |
| Journal | Bone Marrow Transplantation |
| Volume | 12 |
| Issue number | 2 |
| State | Published - Jan 1 1993 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Hematology
- Transplantation
Cite this
Use of recombinant GM-CSF following allogeneic BMTs for aplastic anemia. / Chap, L.; Schiller, G.; Nimer, Stephen D.
In: Bone Marrow Transplantation, Vol. 12, No. 2, 01.01.1993, p. 173-175.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Use of recombinant GM-CSF following allogeneic BMTs for aplastic anemia
AU - Chap, L.
AU - Schiller, G.
AU - Nimer, Stephen D
PY - 1993/1/1
Y1 - 1993/1/1
N2 - GM-CSF has been used successfully in autologous BMTs, and more recently in patients undergoing allogeneic BMT, for acute or chronic leukemia. We report two patients with hepatitis-related aplastic anemia who received recombinant human GM-CSF following HLA-identical sibling allogeneic BMTs. Both patients were conditioned with CY 200 mg/kg given over 4 days and received GM-CSF at 250 μg/m2 beginning 6 h after marrow infusion and continuing daily until the absolute neutrophil count was > 1.0 X 109/l for 2 days. Both patients had prompt engraftment, achieving an absolute neutrophil count of > 0.5 X 109/l on day 13. Neither patient had side-effects attributable to the GM-CSF although one patient developed severe acute GVHD after the cessation of GM-CSF therapy. Our experience suggests that GM-CSF can be safely used in aplastic anemia patients undergoing BMT and that GM-CSF may be useful to decrease the incidence of graft failure associated with less intensive conditioning regimens.
AB - GM-CSF has been used successfully in autologous BMTs, and more recently in patients undergoing allogeneic BMT, for acute or chronic leukemia. We report two patients with hepatitis-related aplastic anemia who received recombinant human GM-CSF following HLA-identical sibling allogeneic BMTs. Both patients were conditioned with CY 200 mg/kg given over 4 days and received GM-CSF at 250 μg/m2 beginning 6 h after marrow infusion and continuing daily until the absolute neutrophil count was > 1.0 X 109/l for 2 days. Both patients had prompt engraftment, achieving an absolute neutrophil count of > 0.5 X 109/l on day 13. Neither patient had side-effects attributable to the GM-CSF although one patient developed severe acute GVHD after the cessation of GM-CSF therapy. Our experience suggests that GM-CSF can be safely used in aplastic anemia patients undergoing BMT and that GM-CSF may be useful to decrease the incidence of graft failure associated with less intensive conditioning regimens.
UR - http://www.scopus.com/inward/record.url?scp=0027235740&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027235740&partnerID=8YFLogxK
M3 - Article
C2 - 8401368
AN - SCOPUS:0027235740
VL - 12
SP - 173
EP - 175
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 2
ER -